![The SRC/p160 family of coregulators.\
Panel A shows the domain structure of human (*h*) SRC-1, -2, and -3 proteins. The basic helix loop helix, Per/ARNT/Sim, receptor interaction and activation domains are indicated by bHLH, PAS, RID, and AD, respectively. The amino acid region associated with histone acetyl transferase (HAT) activity in SRC-1 and -3 is also denoted; Q indicates the glutamine-rich region. Also shown is the similarity and (identity) of amino acid sequences within key functional domains of SRC members. Overall amino acid similarity and (identity) between SRC members is: hSRC1/2, 54% (46%); hSRC1/3, 50% (43%); and hSRC2/3, 55% (48%). Amino acid sequence alignments were conducted using *LALNVIEW* software (Duret et al., 1996). Panel B shows an schematic model in which the pairing of SRC-2 with PR at the genome comprises part of a dynamic multiprotein transcriptional complex in which such co-coregulators as p300 (Chen et al., 2000a), CARM-1 (Chen et al., 1999), FLASH (Kino et al., 2004), GAC63 (Chen et al., 2005), and CoCoA (Kim and Stallcup, 2004) differentially assemble and disassemble depending on a particular input signal, such as a distinct phosphorylation event mediated by a growth factor or cell survival signal-induced kinase.](nrs05011.f1){#fig1}

![Abrogation of uterine SRC-2 results in a block in embryo implantation and a partial decidual response.\
In panel A, arrows show the location of implantation sites in the uterus (1) of a SRC-2^flox/flox^ (or wild-type (WT)) mouse (5.5 days post coitum (d.p.c.)). However, implantation sites were not detected in uteri from similarly treated PR^Cre/+^SRC-2^flox/flox^ (2) mice. The average number of implantation sites per genotype per total number of mice examined is tabulated. In panel B, the gross morphological response of the left (L) uterine horn to a deciduogenic stimulus for SRC-2^flox/flox^ (1), PR^Cre/+^SRC-2^flox/flox^ (2), and PR^Cre/+^SRC-2^flox/flox^ SRC-1KO trigenic (3) mice is shown. The right (R) uterine horn represents the unstimulated control. Although the PR^Cre/+^SRC-2^flox/flox^ uterus (2) exhibits a limited decidual response, note the absence of a decidual response in the PR^Cre/+^SRC-2^flox/flox^ SRC-1KO trigenic uterus (3). Panel C graphically presents the average weight ratios (± standard deviation (SD)) of stimulated (L) to control (R) horn for SRC-2^flox/flox^ (1), PR^Cre/+^SRC-2^flox/flox^ (2), and PR^Cre/+^SRC-2^flox/flox^SRC-1KO trigenic (3) uteri. Western analysis in panel D reveals uterine tissue from untreated adult virgin SRC-2^flox/flox^ (1) and PR^Cre/+^SRC-2^flox/flox^ (2) mice show equivalent levels of uterine SRC-1 and SRC-3 (loading control is β-actin). Modified from (Mukherjee et al., 2006b) (Copyright (2006) American Society for Microbiology).](nrs05011.f2){#fig2}

![Absence of mammary SRC-2 function blocks progestin-induced ductal side-branching and alveologenesis.\
Panels A and B show whole-mounts of mammary glands from SRC-2^flox/flox^ and PR^Cre/+^SRC-2^flox/flox^ mice (following three weeks of estrogen plus progesterone (EP) exposure), respectively. Unlike the SRC-2^flox/flox^ mammary gland (positive control), note the marked reduction in branching morphogenesis (black arrow) in the PR^Cre/+^SRC-2^flox/flox^ gland. Panels C and D represent hematoxylin and eosin (H&E) stained sections of tissue shown in panels A and B, respectively. Compared to the SRC-2^flox/flox^ gland (panel C), note the conspicuous reduction in the epithelial compartment in the PR^Cre/+^SRC-2^flox/flox^ gland (panel D (arrowhead)). The graph in panel E displays the average percentage of mammary epithelial cells (± standard deviation (S.D.)) positive for BrdU incorporation in the hormone-treated SRC-2^flox/flox^ and PR^Cre/+^SRC-2^flox/flox^ glands. Inset shows an SRC-2^flox/flox^ (1) and PR^Cre/+^SRC-2^flox/flox^ (2) immunoblot for mammary SRC-1 and -3. In comparison to SRC-2^flox/flox^, changes in SRC-1 and -3 protein levels are not observed in the PR^Cre/+^SRC-2^flox/flox^ mammary gland (β-actin acts as a loading control). Scale bars in panels A and C apply to B and D, respectively. Modified from (Mukherjee et al., 2006b) (Copyright (2006) American Society for Microbiology).](nrs05011.f3){#fig3}

![Steroid hormone responsive tissues express SRC-2 in the human.\
Panel A shows the increase in ligand-dependent transactivational potency of human PR-B is dependent on increased levels of human SRC-2 (red bars ± S.D.); in the absence of ligand, this increase is not observed (blue bars). For these experiments, human PR-B; SRC-2 (both cloned into pCR3.1) and the luciferase reporter pGRE.E1b.LUC were transiently cotransfected into HeLa cells in the presence or absence of 10^-7^M R5020, as described previously (Lonard et al., 2004); results are expressed in relative light units (RLU). Panel B shows SRC-2 is expressed in the majority of epithelial cells of the human prostate (black arrow), an established cellular target for androgen receptor action (Culig et al., 2002); note: the stromal compartment registers negative for SRC-2 expression (blue arrow). Panels C and D show transverse sections of the luminal and stromal compartment (with surrounding stroma) of the human endometrium stained for PR and SRC-2 expression, respectively. Note that PR and SRC-2 are detected in nuclei of the same cell types in both cellular compartments (black and red arrows, respectively). The blue arrow in panels C and D highlights a stromal cell negative for PR and SRC-2 expression, respectively; scale bar in panel C applies to panel D. Endometrial biopsies were obtained by endometrial pipelle from healthy women with normal cycles (aged between 18-35 years) during the mid-secretory (luteal) phase of the menstrual cycle (days 20-24, which is based on the ideal 28 day cycle, in which day 1 represents the first day of menstrual flow and day 14 the day of ovulation); cycle phase was determined relative to the timing of the urinary luteinizing hormone (LH) surge. Immunohistochemical detection of human SRC-2 and PR was undertaken using established methods previously reported by our group (Lee et al., 2005; Mukherjee et al., 2006b). Panel E shows a representative example of a normal type 1 terminal ductal lobular unit (TDLU) of the human breast in which SRC-2 expression is restricted to the epithelial compartment (black arrow). Panel F is a higher magnification of the region indicated by the black arrow in panel E. Note that SRC-2 expression is confined to a subset of epithelial cells of the TDLU (black arrow indicates an epithelial cell scoring positive for SRC-2 expression, whereas the red arrow highlights an epithelial cell which is negative for SRC-2 expression; blue arrow denotes a stromal cell which is negative for SRC-2 expression). Interestingly, the spatial expression pattern of mammary SRC-2 resembles that previously reported for ER-α and PR in the human breast (Clarke et al., 1997). With institutional review board approval, human tissue samples were obtained from Baylor College of Medicine affiliated hospitals. Modified from (Mukherjee et al., 2006a) (Copyright (2006) Elsevier, B.V.).](nrs05011.f4){#fig4}

Family ties: SRC-2 is a member of the steroid receptor coactivator/p160 family
==============================================================================

Pioneering *in vitro* studies by the O'Malley group revealed that the transactivational potency of agonist bound progesterone receptor (PR) can be significantly enhanced by increasing the cellular level of members of the steroid receptor coactivator (SRC/p160) family of coregulators, reviewed in \[[@r39]\]. The SRC/p160 family consists of three members: SRC-1 (ERAP140/ERAP160/NcoA-1); SRC-2 (TIF-2/GRIP-1/NcoA-2); and SRC-3 (p/CIP/RAC3/AIB1/TRAM-1/ACTR/NcoA-3); reviewed in \[[@r32]\]. To enhance nuclear receptor (NR)-mediated transactivation, each SRC family member has been shown to directly contact - through discreet LXXLL motifs within their NR interaction domain ([Figure 1](#fig1){ref-type="fig"}) - the highly conserved activation 2 domain located in the C-terminal region of NRs. Furthermore, two activation domains (AD1 and AD2) positioned in the C-terminal region of each SRC are responsible for recruiting secondary coregulators (or co-coregulators). For example, AD1 is known to interact with histone acetyltransferases (HATs) p300 and the related cyclic AMP-response element binding protein (CREB)-binding protein (CBP), whereas AD2 is known to recruit arginine methyltransferases such as coactivator-associated arginine methyltransferase 1 (CARM1), reviewed in \[[@r65]\]. The histone-modifying activities of these secondary coregulators (in addition to the weak intrinsic HAT activity of SRC members) facilitate local chromatin remodeling that allows the general transcriptional machinery open access to promoter regions of NR target genes. Apart from histones, these co-coregulators have been shown to posttranslationally modify other target proteins (i.e., other coregulators and transcription factors) within the transcriptional complex. The N-terminally positioned basic helix loop helix-Per/ARNT/Sim (bHLH-PAS) domain is the most conserved structural motif among SRC members ([Figure 1](#fig1){ref-type="fig"}) and is also responsible for co-opting additional coregulators and transcription factors. For SRC-2, these coregulators include coiled-coil coactivator (CoCoA) \[[@r25]\], flightless-I (Fli-I) \[[@r31]\], GRIP1-associated coactivator 63 (GAC63) \[[@r7]\], as well as the transcription factors myocyte-enhancer factor 2C (MEF-2C) \[[@r6]\] and TEF4 \[[@r2]\]. In the case of other regulatory proteins, the bHLH-PAS motif has been shown to be involved in both DNA and ligand binding \[[@r64]; [@r23]\], indicating that this structural domain feature may be involved in SRC regulatory functions beyond those currently known.

Superimposed on the myriad of protein-protein interactions that enable SRC-2 to relay (and control) signaling inputs dispatched from ligand-bound NR to the general transcriptional complex, a multiplicity of interacting signaling inputs (i.e., phosphorylation events triggered by extracellular growth and cell survival factors \[[@r11]; [@r14]\]) are also being transduced by SRC-2 within the multicomponent transcriptional machinery. Although SRC-2 has been primarily considered a coactivator, a subset of investigations provide strong support for a corepressor role for SRC-2 within certain cellular contexts \[[@r18]; [@r21]; [@r46]; [@r62]\]; these studies highlight the versatility and complexity of this multifunctional coregulator.

While *in vitro* experiments disclosed the existence of the SRC family, subsequent experimental mouse genetics would uncover important overlapping and non-overlapping roles for the three SRCs in progestin-initiated signaling events *in vivo*. Further underscoring their multifunctional properties, mouse studies have also uncovered critical roles for each SRC in signaling processes that reside outside the physiologic area of progestin control.

A subgroup of progestin-dependent physiological processes require SRC members: insights from mouse studies
==========================================================================================================

The SRC-1 knockout (KO) mouse was shown to display an attenuated decidual response in the uterus \[[@r61]\], suggesting that this coregulator (in concert with others) is required for complete manifestation of this morphological response, which requires initial progesterone stimulation. Although the SRC-3KO exhibits a normal decidual response, a partial block in hormone-induced mammary ductal side-branching and alveologenesis is observed in this animal \[[@r52]\]. Collectively, these observations support the proposal that SRC-1 and -3 are required for a subgroup of PR-mediated transcriptional responses in the uterus and mammary gland, respectively. Investigations on the PR activity indicator (PRAI) model provide further support for this supposition \[[@r19]; [@r20]\]. Mouse studies have also underscored important roles for SRC-1 and SRC-3 in areas of normal physiology and disease which are outside the realm of progesterone control, these include: cell growth \[[@r51]; [@r52]\], metabolism \[[@r35]; [@r50]\], thyroid hormone-based physiology \[[@r55]\], bone homeostasis \[[@r40]\], prostate biology \[[@r56]\] and B-cell lymphoma developmental progression \[[@r9]\].

In contrast to KOs for SRC-1 and -3, the global KO for SRC-2 (termed: Transcriptional Intermediary Factor 2 KO (or TIF2^-/-^)) displays striking reproductive abnormalities in both sexes \[[@r15]\]. In the female, abrogation of SRC-2 function triggers placental hypoplasia, which results in a severe hypofertility defect. Subsequent studies found that TIF2^-/-^ pups (both sexes) are significantly underrepresented in litters from TIF2^+/-^ crosses (TIF2^-/-^ females resulting from such crosses are infertile (personal observations)). Similar to KOs for SRC-1 and -3, global ablation of SRC-2 function results in physiological defects not directly linked to reproductive biology, such as a decrease in early postnatal survival \[[@r38]\], a breakdown in energy homeostasis \[[@r24]\], as well as elaboration of insidious adrenocortical insufficiency \[[@r44]\]).

Cell lineage-specific abrogation of SRC-2 function in the mouse reveals a critical coregulator role for SRC-2 in a subset of physiological processes that require progesterone action
=====================================================================================================================================================================================

The placental defect exhibited by the global KO for SRC-2, in conjunction with the recent observation that a subset of murine cell lineages express both PR and SRC-2 \[[@r42]\], suggested that SRC-2 (like SRC-1 and -3) may occupy a critical coregulator role in a subgroup of physiological processes that require PR function. To test this hypothesis, a PR^Cre/+^SRC-2^flox/flox^ bigenic mouse was created \[[@r42]\] by crossing a PR^Cre/+^ knockin mouse \[[@r47]\] with a SRC-2^flox/flox^ mouse in which exon 11 of the SRC-2 gene was floxed to enable cre-mediated excision \[[@r15]\]; exon 11 encodes the receptor-interacting domain (RID). Therefore, the PR^Cre/+^SRC-2^flox/flox^ bigenic is designed to abrogate SRC-2 function specifically in cell lineages that are PR positive \[[@r42]\]. The utility of this genetic strategy is that SRC-2's role in PR-regulated transcriptional programs can be directly investigated at the whole-animal level without interference from other, unrelated phenotypes resulting from SRC-2's absence (a key advantage over the global KO for SRC-2).

SRC-2 is required for uterine receptivity
=========================================

To date, female and male PR^Cre/+^SRC-2^flox/flox^ mice show normal postnatal development; however, the PR^Cre/+^SRC-2^flox/flox^ female is sterile \[[@r42]\]. Unlike the TIF2^-/-^ mouse, male PR^Cre/+^SRC-2^flox/flox^ mice exhibit normal fertility and neither sex displays phenotypes (outside progestin control) previously described for the TIF2^-/-^ model \[[@r15]\].

The absence of implantation sites along the uterine horn of the PR^Cre/+^SRC-2^flox/flox^ mouse (5.5 days post-coitum) is the primary underlying cause for the infertility defect displayed by the PR^Cre/+^SRC-2^flox/flox^ female ([Figure 2](#fig2){ref-type="fig"}A). This result suggests a pivotal role played by SRC-2 in the early cellular changes in the uterus that are required for embryo implantation. Although the SRC-2^flox/flox^ uterus (a positive control) exhibits a full decidual response to an artificial deciduogenic stimulus ([Figure 2](#fig2){ref-type="fig"}B and C), the PR^Cre/+^SRC-2^flox/flox^ uterus displays only a partial decidual response ([Figure 2](#fig2){ref-type="fig"}B and C). These findings support the proposal that a subgroup of PR-mediated transcriptional events are dependent on SRC-2 to launch a complete decidual reaction. The incomplete decidual response phenotype shared by the SRC-1KO \[[@r61]\] and PR^Cre/+^SRC-2^flox/flox^ mouse suggests that both SRC coregulators may be required together in PR-mediated signaling cascades that result in a fully decidualized uterus. To test this hypothesis, the SRC-1KO mutation was introduced into the PR^Cre/+^SRC-2^flox/flox^ germline to generate a PR^Cre/+^SRC-2^flox/flox^ SRC-1KO trigenic model. [Figure 2](#fig2){ref-type="fig"}B and C shows that the trigenic uterus fails to mount a decidual response, thereby furnishing essential *in vivo* support for a cooperative involvement for SRC-1 and SRC-2 in the progesterone-dependent decidual reaction. Note that the PR^Cre/+^SRC-2^flox/flox^ uterine phenotype is not explained by changes in the normal levels of uterine SRC-1 and/or SRC-3 protein ([Figure 2](#fig2){ref-type="fig"}D).

In contrast to the uterus, ovarian and pituitary function is not compromised in the PR^Cre/+^SRC-2^flox/flox^ mouse, suggesting that PR enlists other coregulators in these systems (normal ovarian and pituitary functionality is severely diminished in the PRKO \[[@r59]\]). Furthermore, SRC-2 is not required for progesterone-inhibition of PR expression or suppression of estrogen-induced luminal epithelial proliferation in the uterus. Collectively, these observations suggest that the selective enlistment of SRC-2 by PR in female reproductive tissues may provide one explanation as to why different reproductive tissues display different responses to the same progesterone signal.

Having disclosed a central role for uterine SRC-2 in murine peri-implantation biology, future questions to be addressed include: (1) Is uterine SRC-2 expression in the epithelial, stromal, or both cellular compartments required for the development of the receptive uterus? (2) Is SRC-2 expressed in the embryonic-derived trophectoderm? If so, is trophectoderm-derived SRC-2 required for embryo implantation? (3) Does uterine SRC-2 possess coregulator functions necessary for later stages of pregnancy? For example, in the regulation of the onset of parturition; and (4) Does SRC-2 have a role in the etiopathogenesis of such endometrial disorders as uterine hyperplasia and/or endometriosis?

Postnatal mammary morphogenesis requires SRC-2 function
=======================================================

The detection of SRC-2 protein in mammary epithelial cells that are PR positive \[[@r42]\] suggested that mammary SRC-2 may occupy a crucial role in PR-mediated proliferative programs which result in ductal side-branching and alveolar morphogenesis in the mammary gland of the adult. This assumption was supported by the observation that the PR^Cre/+^SRC-2^flox/flox^ mammary gland fails to exhibit the typical morphological changes that occur with combined estrogen and progestin exposure ([Figure 3](#fig3){ref-type="fig"}A-D). Like the PRKO \[[@r60]\], the underlying cause of the PR^Cre/+^SRC-2^flox/flox^ mammary phenotype is a failure of the mammary epithelium to proliferate in response to hormone ([Figure 3](#fig3){ref-type="fig"}E). These results support an essential role for SRC-2 in progesterone-induced signaling programs which are required for mammary morphogenesis in the adult. Of note, the PR^Cre/+^SRC-2^flox/flox^ mammary defect was not compensated for by SRC-3 ([Figure 3](#fig3){ref-type="fig"}E). Although SRC-3 has been shown to be involved in steroid-induced mammary morphogenesis \[[@r52]\], as well as tumorigenesis \[[@r28]; [@r29]; [@r48]\], our data to date suggest that SRC-2 and -3 are operationally distinct in the murine mammary epithelial cell. Irrespective of the functional interrelationships between SRC-2 and other members of the SRC family in this tissue, our studies reveal SRC-2 to be an important coactivator for progestin-initiated signaling in the mammary epithelium. An important question for the future will be to determine whether SRC-2 (like SRC-3/AIB-1 \[[@r63]\]) can act as a mammary oncogene.

Relevance to the human...
=========================

Although state-of-the-art genetics demonstrated a critical role for SRC-2 in a subset of progesterone responses in the uterus and mammary gland of the mouse, whether these findings translate to the human is now an important research focus. As previously shown \[[@r22]\], the transactivational potency of the human PR ortholog is significantly enhanced with increasing levels of human SRC-2 ([Figure 4](#fig4){ref-type="fig"}A). These observations provide strong support for a coregulator involvement for SRC-2 in progestin-dependent physiological processes in the human. As further support for this supposition, immunohistochemistry demonstrates that SRC-2 protein is expressed in a subset of steroid-responsive target tissues in the human ([Figure 4](#fig4){ref-type="fig"}B-F). In the case of human prostate, ([Figure 4](#fig4){ref-type="fig"}B), SRC-2 expression is regionally restricted to the epithelial compartment, a known cellular target-site for androgen receptor-mediated signaling and neoplastic transformation \[[@r3]; [@r10]; [@r54]\]. In the human endometrium, immunohistochemical studies clearly demonstrate that SRC-2 and PR are expressed in identical cell types within the stromal and epithelial compartments ([Figure 4](#fig4){ref-type="fig"}C-D); similar findings have been described for the mouse \[[@r42]\].

Similar to the murine mammary gland \[[@r42]\], immunohistochemical investigations have shown that a subgroup of epithelial cells within the normal human breast express SRC-2 ([Figure 4](#fig4){ref-type="fig"}E and F). Interestingly, the punctate spatial expression pattern for SRC-2 in the human breast parallels a similar spatial expression pattern reported for PR in the rodent and human breast \[[@r57]\]. However, whether (like the mouse \[[@r42]\]) SRC-2 and PR localize to identical cells in the human breast has yet to be demonstrated. Further progress in this area is important, as separation of PR positive mammary epithelial cells from PR negative cells that undergo cell division in response to progesterone is now recognized as an evolutionarily conserved feature that underpins a proposed paracrine mechanism action for PR in the normal breast, reviewed in \[[@r13]\].

Conclusions and perspective
===========================

Despite over 200 known coactivators reported \[[@r65]\], it is significant that PR action is singularly dependent on the coregulator functions of SRC-2 for a subgroup of progesterone-induced physiological responses that are necessary for the maintenance of female fertility and postnatal mammary morphogenesis in the mouse.

Overtly distinct from SRC-1 and SRC-3, coregulator properties of which subserve only a selection of progesterone-initiated transcriptional responses either in the uterus or mammary gland, SRC-2 exerts potent coregulator activities in both progesterone target tissues. From a clinical standpoint, the indispensable role of SRC-2 in murine peri-implantation biology demands further study, since recurrent implantation failure is now recognized as a key underlying factor that precludes the establishment of a successful pregnancy \[[@r43]\]). Importantly, abnormal increases in endometrial SRC-2 levels have also been associated with infertility in women with polycystic ovarian syndrome (PCOS) and with a subset of endometrial cancers \[[@r16]; [@r45]\]. Although preliminary, these latter observations suggest a possible connection between perturbation in SRC-2 protein levels and the etiopathogenesis of these uterine disorders.

In the case of the murine mammary gland, previous studies demonstrated that PR action is necessary for parity-induced mammary proliferation, which represents a prerequisite developmental step prior to terminal differentiation of this tissue; importantly, the progesterone signal can also influence breast cancer susceptibility, reviewed in \[[@r13]\]. The finding that SRC-2 ablation results in a mammary phenotype similar to the PRKO mammary defect has prompted three key questions: (1) Can upregulation of SRC-2 expression promote neoplastic transformation in the murine mammary gland? (2) If so, does SRC-2 have an involvement in hormone-responsive breast cancers in the human? and (3) Does the established oncogenic effects of SRC-3 require the presence of SRC-2?

Obviously, addressing these questions will extend our current understanding of progesterone's role in breast cancer promotion and/or progression, and thus may enable the formulation of more powerful diagnostic, prognostic and/or therapeutic approaches in the future clinical containment of this cancer.
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